Susmed - Public Comps and Valuation Multiples

Susmed Overview

About Susmed

Susmed Inc is engaged in the development of medical equipment and software systems Collection and distribution of medical information.

Founded

2015

HQ

Employees

n/a

Website

susmed.co.jp

Sectors

Healthcare Software
Medical Devices
B2B SaaS
Vertical SaaS
DeepTech
HealthTech

Financials

LTM Revenue $2.3M

Last FY EBITDA -$2.5M

EV

$35.6M

Valuation Multiples

Multiples.vc

Valuation Multiples for 12K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Browse Valuation Multiples

Susmed Financials

Susmed has a last 12-month revenue (LTM) of $2.3M and a last 12-month EBITDA of n/a.

In the most recent fiscal year, Susmed achieved revenue of $2.4M and an EBITDA of -$2.5M.

Susmed expects next 12-month revenue of XXX and NTM EBITDA of XXX

See Susmed valuation multiples based on analyst estimates

Susmed P&L

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Revenue	$2.3M	XXX	$2.4M	XXX	XXX	XXX
Gross Profit	$2.3M	XXX	$2.3M	XXX	XXX	XXX
Gross Margin	100%	XXX	97%	XXX	XXX	XXX
EBITDA	n/a	XXX	-$2.5M	XXX	XXX	XXX
EBITDA Margin	n/a	XXX	-105%	XXX	XXX	XXX
EBIT	-$2.5M	XXX	-$2.5M	XXX	XXX	XXX
EBIT Margin	-106%	XXX	-107%	XXX	XXX	XXX
Net Profit	-$2.4M	XXX	-$2.5M	XXX	XXX	XXX
Net Margin	-104%	XXX	-104%	XXX	XXX	XXX
Net Debt	XXX	XXX	n/a	XXX	XXX	XXX

Financial data powered by Morningstar, Inc.

Susmed Stock Performance

As of May 30, 2025, Susmed's stock price is JPY 580 (or $4).

Susmed has current market cap of JPY 9.7B (or $66.9M), and EV of JPY 5.2B (or $35.6M).

See Susmed trading valuation data

Susmed Stock Data

EV	Market Cap	Price 1D	Price 1M	Price 3M	Price 12M	EPS
$35.6M	$66.9M	XXX	XXX	XXX	XXX	$-0.15

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Start Free Trial

Susmed Valuation Multiples

As of May 30, 2025, Susmed has market cap of $66.9M and EV of $35.6M.

Susmed's trades at 11.9x EV/Revenue multiple, and -25.8x EV/EBITDA.

Equity research analysts estimate Susmed's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

Susmed has a P/E ratio of -27.3x.

See valuation multiples for Susmed and 12K+ public comps

Susmed Financial Valuation Multiples

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Market cap (current)	$66.9M	XXX	$66.9M	XXX	XXX	XXX
EV (current)	$35.6M	XXX	$35.6M	XXX	XXX	XXX
EV/Revenue	15.2x	XXX	11.9x	XXX	XXX	XXX
EV/EBITDA	n/a	XXX	-25.8x	XXX	XXX	XXX
EV/EBIT	-14.3x	XXX	-25.1x	XXX	XXX	XXX
EV/Gross Profit	15.2x	XXX	n/a	XXX	XXX	XXX
P/E	-27.3x	XXX	-47.8x	XXX	XXX	XXX
EV/FCF	n/a	XXX	-65.9x	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Susmed Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Start Free Trial

Susmed Margins & Growth Rates

Susmed's revenue per employee in the last FY averaged n/a, while opex per employee averaged n/a for the same period.

Susmed's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Susmed's rule of X is unknown (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

See operational valuation multiples for Susmed and other 12K+ public comps

Susmed Operational Valuation Multiples

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Revenue Growth	n/a	XXX	n/a	XXX	XXX	XXX
EBITDA Margin	n/a	XXX	n/a	XXX	XXX	XXX
EBITDA Growth	n/a	XXX	n/a	XXX	XXX	XXX
Rule of 40	n/a	XXX	n/a	XXX	XXX	XXX
Bessemer Rule of X	XXX	XXX	n/a	XXX	XXX	XXX
Revenue per Employee	XXX	XXX	n/a	XXX	XXX	XXX
Opex per Employee	XXX	XXX	n/a	XXX	XXX	XXX
S&M Expenses to Revenue	XXX	XXX	n/a	XXX	XXX	XXX
G&A Expenses to Revenue	XXX	XXX	n/a	XXX	XXX	XXX
R&D Expenses to Revenue	XXX	XXX	71%	XXX	XXX	XXX
Opex to Revenue	XXX	XXX	203%	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics

Pharma Analytics

Private Equity

ERP Software

Developer Tools

Consumer SaaS

Streaming Platforms

Explore Valuation Multiples by Industry

Start Free Trial